DoW Toxic Exposures Investigator Initiated Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Fiscal Year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award aims to fund research projects that contribute significantly to understanding and improving patient care for diseases linked to military-related toxic exposures. Eligible studies may range from fundamental laboratory investigations to translational research, including preclinical animal model experiments and human subject studies. The program also accommodates research that correlates with existing clinical trials and encourages the use of New Approach Methodologies in research design. This award is managed by the Department of the Army under the Department of Defense and is open to various research proposals addressing the full spectrum of toxic exposure-related health issues. The contract was posted on May 7, 2026, and provides contact support via the eBRAP Help Desk for inquiries. The program seeks to advance scientific knowledge and patient outcomes through innovative and impactful research initiatives focused on military-related toxic exposures.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used.
